Tech Company Financing Transactions
Decibel Therapeutics Funding Round
Decibel Therapeutics, based in Boston, secured $55 million in investment from Bessemer Venture Partners, Foresite Capital and GV.
Transaction Overview
Company Name
Announced On
6/20/2018
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance Decibel's clinical and preclinical product candidates as well as to build out its comprehensive hearing drug discovery and development platform and capabilities.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1325 Boylston St. 500
Boston, MA 02215
USA
Boston, MA 02215
USA
Phone
Website
Email Address
Overview
Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laurence Reid
Chief Financial Officer
Elisabeth Leiderman
Chief Scientific Officer
John Keilty
Chief Scientific Officer
John Lee
Vice President
Joseph Burns
Vice President
Adam Palermo
Vice President
Janeta Popovici-Muller
Vice President
Jonathon Whitton
Vice President
Heather Wolff
VP - Finance
Ronald Vigliotta
VP - Human Resources
Anna Trask
Browse more venture capital transactions:
Prev: 6/20/2018: Vbrick venture capital transaction
Next: 6/20/2018: SigFig venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs